البحث عن طبيب

Ravi V. Durvasula, M.D.

طلب موعد

المنشورات

  1. Attieh RM, Roach D, Wadei HM, Parikh N, Me HM, Durvasula RV, Oring J. Case Report: Early-Onset Adenovirus Nephritis Without Hemorrhagic Cystitis Following Kidney Transplantation. Transplant Proc. 2024 Jun; 56 (5):1196-1199 Epub 2024 June 08
    View PubMed
  2. Rajani AJ, Raval DM, Chitale RA, Kempaiah P, Elwasila SM, Durvasula R, Oring J. Half a Century in Hiding: A Unique Case of Tuberculoid Leprosy with an Unprecedented Incubation Period. Am J Case Rep. 2024 Feb 14; 25:e942048
    View PubMed
  3. Rajani AJ, Raval D, Chitale R, Durvasula R, Oring J, Powers R. A rare case of scedosporium apiospermum osteomyelitis in an immunocompetent patient. IDCases. 2024; 35:e01929 Epub 2024 Jan 30
    View PubMed
  4. Godart GA, Elwasila SM, Durvasula RV. A rare case of candida osteomyelitis of the mandible associated with osteoradionecrosis and biofilm formation. IDCases. 2024; 37:e02029 Epub 2024 July 18
    View PubMed
  5. Rajani AJ, Roach D, Raval D, Amin J, Kempaiah P, Chitale R, Durvasula R, Oring J. A systemic review of Mycobacterium nebraskense case reports up to october 2023, featuring our unique case study. Int J Mycobacteriol. 2023 Oct-Dec; 12 (4):443-447
    View PubMed
  6. Westlund KN, Montera MA, Goins AE, Alles SRA, Afaghpour-Becklund M, Bartel R, Durvasula R, Kunamneni A. Corrigendum to "Single-chain fragment variable antibody targeting cholecystokinin-B receptor for pain reduction" [Neurobiol. Pain 10 (2021) 100067]. Neurobiol Pain. 2023 Aug-Dec; 14:100127 Epub 2023 Apr 05
    View PubMed
  7. Kunamneni A, Montera MA, Durvasula R, Alles SRA, Goyal S, Westlund KN. Rapid Generation and Molecular Docking Analysis of Single-Chain Fragment Variable (scFv) Antibody Selected by Ribosome Display Targeting Cholecystokinin B Receptor (CCK-BR) for Reduction of Chronic Neuropathic Pain. Int J Mol Sci. 2023 Jul 3; 24 (13) Epub 2023 July 03
    View PubMed
  8. Prabhakaran D, Day GS, Munipalli B, Rush BK, Pudalov L, Niazi SK, Brennan E, Powers HR, Durvasula R, Athreya A, Blackmon K. Neurophenotypes of COVID-19: Risk factors and recovery outcomes. Brain Behav Immun Health. 2023 Jul; 30:100648 Epub 2023 June 04
    View PubMed
  9. Gupta Y, Savytskyi OV, Coban M, Venugopal A, Pleqi V, Weber CA, Chitale R, Durvasula R, Hopkins C, Kempaiah P, Caulfield TR. Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. Mol Aspects Med. 2023 Jun; 91:101151 Epub 2022 Oct 28
    View PubMed
  10. Asiedu SO, Gupta Y, Nicolaescu V, Gula H, Caulfield TR, Durvasula R, Kempaiah P, Kwofie SK, Wilson MD. Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure. Int J Mol Sci. 2023 Apr 12; 24 (8)
    View PubMed
  11. Mohammad TSH, Gupta Y, Reidl CT, Nicolaescu V, Gula H, Durvasula R, Kempaiah P, Becker DP. In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. Int J Mol Sci. 2023 Mar 7; 24 (6) Epub 2023 Mar 07
    View PubMed
  12. Gupta Y, Sharma N, Singh S, Romero JG, Rajendran V, Mogire RM, Kashif M, Beach J, Jeske W, Poonam Poonam, Ogutu BR, Kanzok SM, Akala HM, Legac J, Rosenthal PJ, Rademacher DJ, Durvasula R, Singh AP, Rathi B, Kempaiah P. The Multistage Antimalarial Compound Calxinin Perturbates P. falciparum Ca(2+) Homeostasis by Targeting a Unique Ion Channel. Pharmaceutics. 2022 Jun 28; 14 (7) Epub 2022 June 28
    View PubMed
  13. Gupta Y, Goicoechea S, Romero JG, Mathur R, Caulfield TR, Becker DP, Durvasula R, Kempaiah P. Repurposing Lansoprazole and Posaconazole to treat leishmaniasis: Integration of in vitro testing, pharmacological corroboration, and mechanisms of action. J Food Drug Anal. 2022 Mar 15; 30 (1):128-149
    View PubMed
  14. Gupta Y, Maciorowski D, Medernach B, Becker DP, Durvasula R, Libertin CR, Kempaiah P. Iron dysregulation in COVID-19 and reciprocal evolution of SARS-CoV-2: Natura nihil frustra facit. J Cell Biochem. 2022 Mar; 123 (3):601-619 Epub 2022 Jan 08
    View PubMed
  15. Gupta Y, Goicoechea S, Pearce CM, Mathur R, Romero JG, Kwofie SK, Weyenberg MC, Daravath B, Sharma N, Poonam, Akala HM, Kanzok SM, Durvasula R, Rathi B, Kempaiah P. The emerging paradigm of calcium homeostasis as a new therapeutic target for protozoan parasites. Med Res Rev. 2022 Jan; 42(1):56-82. Epub 2021 Apr 13.
    View PubMed
  16. Verma JS, Libertin CR, Gupta Y, Khanna G, Kumar R, Arora BS, Krishna L, Fasina FO, Hittner JB, Antoniades A, van Regenmortel MHV, Durvasula R, Kempaiah P, Rivas AL. Multi-Cellular Immunological Interactions Associated With COVID-19 Infections. Front Immunol. 2022; 13:794006 Epub 2022 Feb 24
    View PubMed
  17. Westlund KN, Montera MA, Goins AE, Alles SRA, Suri N, McIlwrath SL, Bartel R, Durvasula RV, Kunamneni A. Single-Dose P2 X4R Single-Chain Fragment Variable Antibody Permanently Reverses Chronic Pain in Male Mice. Int J Mol Sci. 2021 Dec 19; 22(24).
    View PubMed
  18. Gupta Y, Maciorowski D, Zak SE, Jones KA, Kathayat RS, Azizi SA, Mathur R, Pearce CM, Ilc DJ, Husein H, Herbert AS, Bharti A, Rathi B, Durvasula R, Becker DP, Dickinson BC, Dye JM, Kempaiah P. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. Methods. 2021 Nov; 195:57-71 Epub 2021 Jan 14
    View PubMed
  19. Kumar S, Gupta Y, Zak SE, Upadhyay C, Sharma N, Herbert AS, Durvasula R, Potemkin V, Dye JM, Poonam Poonam, Kempaiah P, Rathi B. A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): in silico and in vitro investigations. RSC Med Chem. 2021 Oct 20; 12 (10):1757-1764 Epub 2021 Aug 18
    View PubMed
  20. Gupta Y, Kumar S, Zak SE, Jones KA, Upadhyay C, Sharma N, Azizi SA, Kathayat RS, Poonam Poonam, Herbert AS, Durvasula R, Dickinson BC, Dye JM, Rathi B, Kempaiah P. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Bioorg Med Chem. 2021 Oct 1; 47:116393 Epub 2021 Sept 04
    View PubMed
  21. Westlund KN, Montera MA, Goins AE, Alles SRA, Afaghpour-Becklund M, Bartel R, Durvasula R, Kunamneni A. Single-chain Fragment variable antibody targeting cholecystokinin-B receptor for pain reduction. Neurobiol Pain. 2021 Aug-Dec; 10:100067 Epub 2021 July 15
    View PubMed
  22. Gupta Y, Maciorowski D, Zak SE, Kulkarni CV, Herbert AS, Durvasula R, Fareed J, Dye JM, Kempaiah P. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. Int J Biol Macromol. 2021 Jul 31; 183:203-212 Epub 2021 Apr 26
    View PubMed
  23. Gomes B, Ogelio H, Brant F, Pereira-Pinto CJ, Workman MJ, Costa M, Lima JBP, Martins AJ, Ramalho-Ortigao M, Durvasula R, Hurwitz I, David MR, Genta FA. High larvicidal efficacy of yeast-encapsulated orange oil against Aedes aegypti strains from Brazil. Parasit Vectors. 2021 May 22; 14 (1):272
    View PubMed
  24. Maciorowski D, Ogaugwu C, Durvasula SR, Durvasula R, Kunamneni A. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. SLAS Discov. 2021 Mar; 26 (3):311-329 Epub 2020 Dec 15
    View PubMed
  25. Rivas A, Piccinini R, Hoogesteijn A, Kempaiah P, Fasina F, Hittner J, Durvasula RV. Exploring the early months of the Italian COVID-19 epidemic: Interconnections between statistical methodology, data interpretation and public policy Travel Medicine and Infectious Diseases. 2021.
  26. Kunamneni A, Montera M, Goins A, Bartel R, Alles S, Durvasula RV. Single-Chain Fragment Variable Antibodies Targeting Cholecystokinin-B Receptor Reduce Chronic Pain Behaviors Neurobiology of Pain. 2021.
  27. Iandiorio M, Fazio J, Kempaiah P, Durvasula RV, Regenmortel M, Rivas A. Personalized and dynamic antibiograms- an exploration in seven infectious syndromes MedRxiv doi: https://doi.org/10.1101/2021.01.22.21249954. 2021.
  28. Kumar S, Sharma PP, Shankar U, Kumar D, Joshi SK, Pena L, Durvasula R, Kumar A, Kempaiah P, Poonam Poonam, Rathi B. Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies. J Chem Inf Model. 2020 Dec 28; 60 (12):5754-5770 Epub 2020 June 18
    View PubMed
  29. Maciorowski D, Idrissi SZE, Gupta Y, Medernach BJ, Burns MB, Becker DP, Durvasula R, Kempaiah P. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. SLAS Discov. 2020 Dec; 25 (10):1108-1122 Epub 2020 Sept 17
    View PubMed
  30. Kumar S, Goicoechea S, Kumar S, Pearce CM, Durvasula R, Kempaiah P, Rathi B, Poonam Poonam. Oseltamivir analogs with potent anti-influenza virus activity. Drug Discov Today. 2020 Aug; 25 (8):1389-1402 Epub 2020 June 15
    View PubMed
  31. Kunamneni A, Ogaugwu C, Bradfute S, Durvasula R. Ribosome Display Technology: Applications in Disease Diagnosis and Control. Antibodies (Basel). 2020 Jun 27; 9(3).
    View PubMed
  32. Gupta Y, Maciorowski D, Mathur R, Pearce CM, Ilc DJ, Husein H, Bharti A, Becker DP, Brijesh R, Bradfute SB, Durvasula R, Kempaiah P. Revealing SARS-CoV-2 Functional Druggability Through Multi-Target CADD Screening of Repurposable Drugs Preprints.org. 2020; 2020050199(DOI: 10.20944/preprints202005.0199.v1.).
  33. Workman MJ, Gomes B, Weng JL, Ista LK, Jesus CP, David MR, Ramalho-Ortigao M, Genta FA, Matthews SK, Durvasula R, Hurwitz I. Yeast-encapsulated essential oils: a new perspective as an environmentally friendly larvicide. Parasit Vectors. 2020 Jan 13; 13 (1):19
    View PubMed
  34. Arora A, Durvasula RV. A Revised Framework for Paratransgenic Control of Vector-borne Diseases Bioengineered invited paper. 2020.
  35. Sharma N, Gupta Y, Bansal M, Singh S, Pathak P, Shahbaaz M, Mathur R, Grishina V, Rajendran V, Poonam P, Durvasula RV, Singh A, Kempaiah P. Multistage Antiplasmodial Activity of Hydroxyethylamine Compounds, In Vitro and In Vivo Evaluations European Journal of Medicinal Chemistry. 2020.
  36. Kunamneni A, Montera M, Suri N, Westlund KN, Alles SR Pappu S, Durvasula RV. Therapeutic anti-P2X4 receptor scFv antibody for chronic neuropathic pain. The FASEB Journal. 2020; 1-1:34.
  37. Kwofie SK, Broni E, Dankwa B, Enninful KS, Kwarko GB, Darko L, Durvasula R, Kempaiah P, Rathi B, Miller Iii WA, Yaya A, Wilson MD. Outwitting an Old Neglected Nemesis: A Review on Leveraging Integrated Data-Driven Approaches to Aid in Unraveling of Leishmanicides of Therapeutic Potential. Curr Top Med Chem. 2020; 20 (5):349-366
    View PubMed
  38. Kunamneni A, Clarke EC, Ye C, Bradfute SB, Durvasula R. Generation and Selection of a Panel of Pan-Filovirus Single-Chain Antibodies using Cell-Free Ribosome Display. Am J Trop Med Hyg. 2019 Jul; 101 (1):198-206
    View PubMed
  39. Kunamneni A, Montera M, Gott K, Durvasula RV, Westlund K. Generating highly potent and efficacious antibodies to the cholecystokinin B (CCK-B) receptor by ribosome display for the treatment of neuropathic pain. The FASEB Journal. 2019; 33(1):658.2.
  40. Kunamneni A, Bradfute S, Kang A, Durvasula RV. A Rapid antigen and antibody ribosomal display for the isolation of a panel of Xylella fastidiosa PilB-specific single chain antibodies Procceedings of the National Academy of Sciences USA under revision. 2019.
  41. Arora A, Miller T, Durvasula RV. Transmission of Pantoea agglomerans- a paratransgenic control agent- within a Homalodisca vitripennis population J Applied Entomology. 2019. Epub 2020 Jan 01.
  42. Rivas A, Hoogensteijn A, Durvasula RV, Van Regenmortel M. Utilizing the properties that characterize biological complexity to assess and prevent immunological ambiguity Frontiers in Immunology under revision. 2019.
  43. Rivas AL, Hoogesteijn AL, Antoniades A, Tomazou M, Buranda T, Perkins DJ, Fair JM, Durvasula R, Fasina FO, Tegos GP, van Regenmortel MHV. Assessing the Dynamics and Complexity of Disease Pathogenicity Using 4-Dimensional Immunological Data. Front Immunol. 2019; 10:1258 Epub 2019 June 12
    View PubMed
  44. Miller Iii WA, Teye J, Achieng AO, Mogire RM, Akala H, Ong'echa JM, Rathi B, Durvasula R, Kempaiah P, Kwofie SK. Antimalarials: Review of Plasmepsins as Drug Targets and HIV Protease Inhibitors Interactions. Curr Top Med Chem. 2019; 18 (23):2022-2028
    View PubMed
  45. Arora AK, Pesko KN, Quintero-Hernandez V, Possani LD, Miller TA, Durvasula RV. A paratransgenic strategy to block transmission of Xylella fastidiosa from the glassy-winged sharpshooter Homalodisca vitripennis. BMC Biotechnol. 2018 Aug 22; 18 (1):50
    View PubMed
  46. Kumar Singh A, Rajendran V, Singh S, Kumar P, Kumar Y, Singh A, Miller W, Potemkin V, Poonam Poonam, Grishina M, Gupta N, Kempaiah P, Durvasula R, Singh BK, Dunn BM, Rathi B. Antiplasmodial activity of hydroxyethylamine analogs: Synthesis, biological activity and structure activity relationship of plasmepsin inhibitors. Bioorg Med Chem. 2018 Jul 30; 26 (13):3837-3844 Epub 2018 June 28
    View PubMed
  47. Ogaugwu CE, Cheng Q, Fieck A, Hurwitz I, Durvasula R. Characterization of a Lactococcus lactis promoter for heterologous protein production. Biotechnol Rep (Amst). 2018 Mar; 17:86-92 Epub 2017 Dec 24
    View PubMed
  48. Kunamneni A, Ye C, Bradfute SB, Durvasula R. Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies. PLoS One. 2018; 13 (11):e0205743 Epub 2018 Nov 16
    View PubMed
  49. Tucker JD, Hughes MA, Durvasula RV, Vinetz JM, McGovern VP, Schultz R, Dunavan CP, Wilson ME, Milner DA, LaRocque RC, Calderwood SB, Guerrant RL, Weller PF, Taylor TE. Measuring Success in Global Health Training: Data From 14 Years of a Postdoctoral Fellowship in Infectious Diseases and Tropical Medicine. Clin Infect Dis. 2017 Jun 15; 64 (12):1768-1772
    View PubMed
  50. Fraihi W, Fares W, Perrin P, Dorkeld F, Sereno D, Barhoumi W, Sbissi I, Cherni S, Chelbi I, Durvasula R, Ramalho-Ortigao M, Gtari M, Zhioua E. An integrated overview of the midgut bacterial flora composition of Phlebotomus perniciosus, a vector of zoonotic visceral leishmaniasis in the Western Mediterranean Basin. PLoS Negl Trop Dis. 2017 Mar; 11 (3):e0005484 Epub 2017 Mar 29
    View PubMed
  51. Chatzipanagiotou S, Ioannidis A, Trikka-Graphakos E, Charalampaki N, Sereti C, Piccinini R, Higgins AM, Buranda T, Durvasula R, Hoogesteijn AL, Tegos GP, Rivas AL. Detecting the Hidden Properties of Immunological Data and Predicting the Mortality Risks of Infectious Syndromes. Front Immunol. 2016; 7:217 Epub 2016 June 10
    View PubMed
  52. Arora AK, Forshaw A, Miller TA, Durvasula R. A delivery system for field application of paratransgenic control. BMC Biotechnol. 2015 Jun 23; 15:59 Epub 2015 June 23
    View PubMed
  53. Maleki-Ravasan N, Oshaghi MA, Afshar D, Arandian MH, Hajikhani S, Akhavan AA, Yakhchali B, Shirazi MH, Rassi Y, Jafari R, Aminian K, Fazeli-Varzaneh RA, Durvasula R. Aerobic bacterial flora of biotic and abiotic compartments of a hyperendemic Zoonotic Cutaneous Leishmaniasis (ZCL) focus. Parasit Vectors. 2015 Jan 29; 8:63
    View PubMed
  54. Heerman M, Weng JL, Hurwitz I, Durvasula R, Ramalho-Ortigao M. Bacterial Infection and Immune Responses in Lutzomyia longipalpis Sand Fly Larvae Midgut. PLoS Negl Trop Dis. 2015; 9 (7):e0003923 Epub 2015 July 08
    View PubMed
  55. Durvasula RV, Hurwitz I, Fieck A, Subba Rao DV. Culture, Growth, Pigments and Lipid content of Scenedesmus species An Extremophile Microalga from Soda Dam, New Mexico, in wastewater. Algal Research. 2015; 10.
  56. Arora A, Durvasula RV, Miller T. Use of Taqman Minor Groove Binder Probes to Distinguish Between Two Pathogenic Strains of Xylella fastidiosa. International Journal of Biotech Trends and Technology. 2014; 7:8-13.
  57. Kunamneni A, Durvasula R. Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review. Recent Adv Cardiovasc Drug Discov. 2014; 9 (2):106-21
    View PubMed
  58. Jose C, Klein N, Wyss S, Fieck A, Hurwitz I, Durvasula R. Recombinant Arthrobacter beta-1, 3-glucanase as a potential effector molecule for paratransgenic control of Chagas disease. Parasit Vectors. 2013 Mar 14; 6:65
    View PubMed
  59. Vadrevu SHR, Durvasula RV. Dynamic Models of Infectious Diseases Vector-Borne Diseases Springer. 2013; 1:292.
  60. Hurwitz I, Fieck A, Durvasula R. Antimicrobial peptide delivery strategies: use of recombinant antimicrobial peptides in paratransgenic control systems. Curr Drug Targets. 2012 Aug; 13 (9):1173-80
    View PubMed
  61. Fieck A, Hurwitz I, Jose C, Durvasula RV. Use of antimicrobial peptides for paratransgenic control of infectious diseases Current Drug Targets. 2012; Aug;13(9):1173-80..
  62. Hurwitz I, Jose C, Durvasula RV. Paratransgenic Control of Trypanosoma cruzi Transmission by Triatomine Bugs Psyche: Special Issue on True Bugs (Heteroptera), Chemical Ecology of Invasive and Emerging Pest Species. 2012; 2012:Article ID 178930.
  63. Klein N, Hurwitz I, Durvasula RV. Globalization of Chagas Disease: A Growing Concern in Nonendemic. Epidemiology Research International. 2012; Article ID 136793.
  64. Mao J, Durvasula RV. Lung cancer chemoprevention: current status and future directions. Current Respiratory Care Reports. 2012; 1:9-20.
  65. Bourtzis K, Crook S, Daffonchio D, Durvasula R, Hanboonsong Y, Infante F, Lacava P, Miller T, Vega F. International Entomology American Entomologist. 2012; 58(4):234-235.
  66. Ursic-Bedoya R, Buchhop J, Joy JB, Durvasula R, Lowenberger C. Prolixicin: a novel antimicrobial peptide isolated from Rhodnius prolixus with differential activity against bacteria and Trypanosoma cruzi. Insect Mol Biol. 2011 Dec; 20 (6):775-86 Epub 2011 Sept 12
    View PubMed
  67. Markiv A, Beatson R, Burchell J, Durvasula RV, Kang AS. Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm. BMC Biotechnol. 2011 Nov 30; 11:117
    View PubMed
  68. Hurwitz I, Hillesland H, Fieck A, Das P, Durvasula R. The paratransgenic sand fly: a platform for control of Leishmania transmission. Parasit Vectors. 2011 May 19; 4:82
    View PubMed
  69. Matthews S, Rao VS, Durvasula RV. Modeling horizontal gene transfer (HGT) in the gut of the Chagas disease vector Rhodnius prolixus. Parasit Vectors. 2011 May 14; 4:77
    View PubMed
  70. Markiv A, Anani B, Durvasula RV, Kang AS. Module based antibody engineering: a novel synthetic REDantibody. J Immunol Methods. 2011 Feb 1; 364 (1-2):40-9 Epub 2010 Nov 03
    View PubMed
  71. Hurwitz I, Fieck A, Read A, Hillesland H, Klein N, Kang A, Durvasula R. Paratransgenic control of vector borne diseases. Int J Biol Sci. 2011; 7 (9):1334-44 Epub 2011 Nov 01
    View PubMed
  72. Fieck A, Hurwitz I, Kang AS, Durvasula R. Trypanosoma cruzi: synergistic cytotoxicity of multiple amphipathic anti-microbial peptides to T. cruzi and potential bacterial hosts. Exp Parasitol. 2010 Aug; 125 (4):342-7 Epub 2010 Mar 03
    View PubMed
  73. Subhadra B, Hurwitz I, Fieck A, Rao DV, Rao GS, Durvasula R. Development of paratransgenic Artemia as a platform for control of infectious diseases in shrimp mariculture. J Appl Microbiol. 2010 Mar; 108 (3):831-40 Epub 2009 July 13
    View PubMed
  74. Fieck A, Hurwitz I, Durvasula RV. Synergistic Activity of Multiple Amphipathic Peptides to Potential Bacterial Hosts and Trypanosoma cruzi Experimental Parasitology. 2010; 125(4):342-347.
  75. Subhadra B, Hurwitz I, Fieck A, Subba Rao G, Subba Rao DV, Durvasula RV. Paratransgenic Artemia as a Strategy to Combat Infections of Mariculture J Applied Microbiology. 2009; 108(3): 831-840.
  76. Hillesland H, Read A, Subhadra B, Hurwitz I, McKelvey R, Ghosh K, Das P, Durvasula R. Identification of aerobic gut bacteria from the kala azar vector, Phlebotomus argentipes: a platform for potential paratransgenic manipulation of sand flies. Am J Trop Med Hyg. 2008 Dec; 79 (6):881-6
    View PubMed
  77. Sundaram RK, Hurwitz I, Matthews S, Hoy E, Kurapati S, Crawford C, Sundaram P, Durvasula RV. Expression of a functional single-chain antibody via Corynebacterium pseudodiphtheriticum. Eur J Clin Microbiol Infect Dis. 2008 Jul; 27 (7):617-22 Epub 2008 Mar 06
    View PubMed
  78. Durvasula RV, Sundaram RK, Kirsch P, Hurwitz I, Crawford CV, Dotson E, Beard CB. Genetic transformation of a Corynebacterial symbiont from the Chagas disease vector Triatoma infestans. Exp Parasitol. 2008 May; 119 (1):94-8 Epub 2008 Jan 24
    View PubMed
  79. Durvasula RV, Hurwitz I, Matthews S.. Paratransgenic strategies for control of vector-borne diseases: rewards and risks Entomological Research. 2007; 37 (Supp 1): A36.
  80. Durvasula RV, Hurwitz I, Subhadra B, Matthews S. The spectrum of paratransgenic strategies: from triatomines to shrimp Entomological Research. 2007; 37 (Supp 1): A71.
  81. Dotson EM, Plikaytis B, Shinnick TM, Durvasula RV, Beard CB. Transformation of Rhodococcus rhodnii, a symbiont of the Chagas disease vector Rhodnius prolixus, with integrative elements of the L1 mycobacteriophage. Infect Genet Evol. 2003 Jul; 3 (2):103-9
    View PubMed
  82. Beard CB, Cordon-Rosales C, Durvasula RV. Bacterial symbionts of the triatominae and their potential use in control of Chagas disease transmission. Annu Rev Entomol. 2002; 47:123-41
    View PubMed
  83. Beard CB, Dotson EM, Pennington PM, Eichler S, Cordon-Rosales C, Durvasula RV. Bacterial symbiosis and paratransgenic control of vector-borne Chagas disease. Int J Parasitol. 2001 May 1; 31 (5-6):621-7
    View PubMed
  84. Durvasula RV, Gumbs A, Panackal A, Kruglov O, Taneja J, Kang AS, Cordon-Rosales C, Richards FF, Whitham RG, Beard CB. Expression of a functional antibody fragment in the gut of Rhodnius prolixus via transgenic bacterial symbiont Rhodococcus rhodnii. Med Vet Entomol. 1999 May; 13 (2):115-9
    View PubMed
  85. Durvasula RV , Taneja J. Maintenance of Human, Animal and Plant Pathogen Vectors Science Publishers Inc. Enfield, NA, New Hampshire 03748 USA pp 328. 1999.
  86. Durvasula RV, Panackal A, Taneja J, Gumbs A, Kruglov O, Richards F, Beard CB. A Strategy for Spreading Anti-trypanosomal Genes in Populations of the Chagas disease Vector, Rhodnius prohxus. Annals of The Entomological Society of America. 1999; 92(6):937-943.
  87. Beard CB, Durvasula RV, Richards FF. Bacterial symbiosis in arthropods and the control of disease transmission. Emerg Infect Dis. 1998 Oct-Dec; 4 (4):581-91
    View PubMed
  88. Durvasula RV, Gumbs A, Panackal A, Kruglov O, Aksoy S, Merrifield RB, Richards FF, Beard CB. Prevention of insect-borne disease: an approach using transgenic symbiotic bacteria. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3274-8.
    View PubMed
  89. Durvasula RV, Gumbs A., Panackal A., Kruglov 0., Richards F.F. Prevention of Chagas disease Transmission: An Approach using Transgenic Symbiotic Bacteria Mem. Inst, Oswaldo Cruz, Rio de Janeiro. 1996; 91:31.
  90. Aksoy S., Beard C.B., Durvasula RV, Hull R., Kang A., O'Neill S.L., Richards F.F.. Expression of foreign genes in the symbiotic bacteria in insect vectors Proceedings of the First International Workshop on Transgenesis of Invertebrates of Medical, Agricultural and Aquacultural Importance. 1995.
  91. Conover RJ, Durvasula RV, Roy S, Wang R. Probable Loss of Chlorophyll-derived Pigments During Passage Through the Gut of Zooplankton, and Some of the Consequences Limnology and Oceanography. 1986; 31(4):878-887.